CRMD vs. NATR, BDTX, SLDB, AQST, CHMA, DAWN, ABCL, LQDA, TYRA, and COLL
Should you be buying CorMedix stock or one of its competitors? The main competitors of CorMedix include Nature's Sunshine Products (NATR), Black Diamond Therapeutics (BDTX), Solid Biosciences (SLDB), Aquestive Therapeutics (AQST), Chiasma (CHMA), Day One Biopharmaceuticals (DAWN), AbCellera Biologics (ABCL), Liquidia (LQDA), Tyra Biosciences (TYRA), and Collegium Pharmaceutical (COLL). These companies are all part of the "medical" sector.
Nature's Sunshine Products (NASDAQ:NATR) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk, analyst recommendations and community ranking.
Nature's Sunshine Products presently has a consensus price target of $24.00, indicating a potential upside of 59.57%. CorMedix has a consensus price target of $13.00, indicating a potential upside of 151.94%. Given Nature's Sunshine Products' higher possible upside, analysts plainly believe CorMedix is more favorable than Nature's Sunshine Products.
Nature's Sunshine Products received 146 more outperform votes than CorMedix when rated by MarketBeat users. However, 71.43% of users gave CorMedix an outperform vote while only 62.89% of users gave Nature's Sunshine Products an outperform vote.
Nature's Sunshine Products has a net margin of 3.69% compared to Nature's Sunshine Products' net margin of 0.00%. CorMedix's return on equity of 10.59% beat Nature's Sunshine Products' return on equity.
In the previous week, CorMedix had 1 more articles in the media than Nature's Sunshine Products. MarketBeat recorded 1 mentions for CorMedix and 0 mentions for Nature's Sunshine Products. CorMedix's average media sentiment score of 0.00 equaled Nature's Sunshine Products'average media sentiment score.
Nature's Sunshine Products has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500.
Nature's Sunshine Products has higher revenue and earnings than CorMedix. CorMedix is trading at a lower price-to-earnings ratio than Nature's Sunshine Products, indicating that it is currently the more affordable of the two stocks.
79.4% of Nature's Sunshine Products shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 4.7% of Nature's Sunshine Products shares are owned by company insiders. Comparatively, 3.6% of CorMedix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Nature's Sunshine Products beats CorMedix on 10 of the 16 factors compared between the two stocks.
Get CorMedix News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CorMedix Competitors List
Related Companies and Tools
